Financial Data and Key Metrics Changes - In Q1 2024, the company achieved €208.8 million in revenue, representing a slight 2% decrease compared to the same period in 2023, primarily due to a 23% decline in Shared R&D revenue [27][24] - Adjusted Group EBITDA for Q1 2024 was €7.8 million, marking a 73% decline from the prior year, mainly driven by higher revenues and low overall cost increase [28] - The net debt ratio increased to 2.9, but the company maintained over €500 million in liquidity at the end of Q1 [5] Business Line Data and Key Metrics Changes - Just Evotec Biologics reported revenue of €53.5 million in Q1, reflecting over 380% growth compared to the same period last year [27] - Shared R&D experienced a 23% revenue decline in Q1 2024 versus Q1 2023, which was noted as the strongest in the company's history [24] - The company is focusing on smart partnering and has exited its Orth site and gene therapy business to concentrate on core modalities [11] Market Data and Key Metrics Changes - The company noted a challenging market environment, but a 70% increase in the Discovery Sales Book indicates potential recovery in the second half of 2024 [24][25] - The company is seeing strong traction with customers when offering integrated services that cover multiple steps along the value chain [18] Company Strategy and Development Direction - The company is executing a reset initiative to return to strong profitability, focusing on cost optimization and strategic partnerships [3][11] - The new factory in Toulouse, France, is expected to be fully operational by Q1 2025, which is part of the company's growth strategy [4] - The company is prioritizing investments in R&D and platforms that align with strategic priorities and partner relevance [4][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a recovery in the second half of 2024, despite a challenging first half [40] - The company anticipates that future growth will be driven by a more favorable business mix and efficiency improvement measures [39] - Management acknowledged the need for further innovations in gene therapy but decided to focus R&D investments on areas with stronger long-term potential [106] Other Important Information - The company is in constructive discussions with the Workers Council regarding capacity needs and potential headcount adjustments [12][38] - The company is preparing for a Capital Markets Day in October, which will focus on the Just Evotec Biologics business [35] Q&A Session Summary Question: What is driving the 70% growth in discovery work? - The growth is attributed to integrated offerings that provide near-term margins, although the demand from biotech funding has not significantly improved [43] Question: Can you clarify the EBITDA guidance for 2024? - The guidance suggests a mid-double digit percentage growth, with a target around €95 million [17][47] Question: What are the dynamics for Q2 revenue growth? - Q2 is expected to show similar trends to Q1, with a focus on H2 for more visible revenue growth [54][95] Question: How long does it take for orders to translate into sales? - It typically takes six to eight months for large contracts to translate into revenue, with some faster-moving business taking weeks [101] Question: What is the status of the gene therapy business? - The decision to exit the gene therapy business was made due to technological challenges and the need for further innovations [106]

| --- | --- | --- | |---------------------------------------------|-------|-------------------------------| | | | | | | | | | | | | | Resetting for profitable growth | | | | | | SCIENTIFIC ES ONAL EXCELLENCE | | Evotec SE, Q1 2024 Analyst Call, 2024-05-22 | | | PAGE 2 #RESEARCHNEVERSTOPS This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company ...

Financial Data and Key Metrics Changes - Group revenues for 2023 were €781.4 million, a 4% increase compared to the previous year, despite significant operational impacts from a cyber incident [42][43] - Adjusted Group EBITDA for the year was €66.4 million, marking a 34% decline from last year, largely due to non-recoverable business and reduced capacity utilization in Q2 [44] - Gross margin declined to 22.6% from 23.2% due to the cyber incident and market challenges, with an adjusted gross margin of 27% excluding Just-Biologics [22][43] Business Line Data and Key Metrics Changes - Revenue from Just-Evotec Biologics reached €108.4 million, reflecting a remarkable increase of over 110% compared to the prior year, driven by strong partnerships [12] - The Innovate segment saw growth of more than 30%, primarily due to contract extensions with BMS in neurodegeneration and target protein degradation [45] - Execute segment revenues grew year-over-year, despite being adversely impacted by the cyber incident and a softening market towards the end of the year [46] Market Data and Key Metrics Changes - The share of biotech in the company's business decreased from approximately 40% to 34% due to fewer new funding events, indicating a challenging environment for biotech companies [39] - The company anticipates a market recovery towards 2025, with a cautious outlook for 2024 due to ongoing challenges in the biotech sector [28][39] Company Strategy and Development Direction - The company is focusing on profitability, efficiency, and high performance, with a strategic reset to align with market demands [9][30] - A new management structure has been introduced, including the appointment of a Chief People Officer to enhance organizational alignment and culture [11] - The company plans to optimize its organizational structure and operational model, with a target of generating annualized EBITDA improvements of over €40 million [79] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2023, including a cyber incident that resulted in €70 million in missed revenue, but expressed confidence in the company's ability to recover and grow [21][44] - The outlook for 2024 includes expectations of double-digit revenue growth, with a focus on Just-Evotec Biologics and differentiated offerings [36][80] - Management highlighted the importance of rebuilding momentum in the sales pipeline following the cyber incident and emphasized the need for careful monitoring of market conditions [66][96] Other Important Information - The company has made significant strides in sustainability, reducing Scope 1 and 2 emissions by 29% [23] - The new CEO, Dr. Christian Wojczewski, is expected to lead the company towards a prosperous future, leveraging his experience in transformational change [9][10] Q&A Session Summary Question: What are the expectations for 2024 and 2025? - Management indicated a qualitative guidance for 2024, expecting at least €100 million in EBITDA and €200 million plus in 2025, while acknowledging uncertainties [58][60] Question: What has changed in the market to prompt a more cautious outlook? - Management noted a decline in biotech funding and a challenging environment, leading to a cautious approach despite some early signs of recovery [64][66] Question: How is the order book looking across the broader business? - Management expressed confidence in the order book, indicating a double-digit growing demand and a strong pipeline, particularly in Just-Evotec Biologics [110]

Revenues with partners in % Total Margin • Just – Evotec Biologics +111% PAGE 14 1 Differences may occur due to rounding Market dynamics and Q4 2023 performance triggered business review PAGE 15 PAGE 16 1. 2023 Performance review 2. Priority reset, Guidance & Outlook 3. Questions & Answers For 2024, we expect to continue operating in a challenging market Summary of current "buyer's market" dynamics PoC: Proof of Concept; IPO: Initial Public Offering; VC: Venture Capital; I&I: Inflammation and Immunology Sou ...

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc ...

#researchneverstops | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Evotec SE (NASDAQ:EVO) Business Update Conference Call January 22, 2024 9:00 AM ET Company Participants Volker Braun - SVP, Head of Global IR & ESG Iris Löw-Friedrich - Chairwoman Mario Polywka - Interim CEO Conference Call Participants Charles Weston - RBC Capital Markets Falko Friedrichs - Deutsche Bank Michael Ryskin - Bank of America Merrill Lynch Steven Mah - TD Cowen Christian Ehmann - Warburg Research Operator At this time, it is my pleasure to hand over to Mr. Volker Braun, Head of Global Investor R ...

If you go forward in this presentation and if we jump back to our governance, and to our impact that we want to have as a company, let me highlight that it was important -- that it is very important and you see it on page number 21, that near-term Science Based Targets are validated and approved now. Why is this important because we always said we want to keep our ESG promises and have aligned our commitment here with our partners to follow the Paris goals. And if you go to page 22, we want to thank the ana ...

| --- | --- | --- | |---------------------------------------------------|-------|-------| | | | | | Evotec SE, 9M 2023 results call, 08 November 2023 | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Werner Lanthaler - CEO Laetitia Rouxel - CFO Cord Dohrmann - CSO Matthias Evers - Chief Business Officer Conference Call Participants Peter Verdult - Citigroup James Quigley - Morgan Stanley Wolf Chanoff - Bank of America Steven Mah - TD Cowen Joseph Hedden - Rx Securities Charles Weston - RBC Capital Markets Douglas Tsao - H.C. Wainwright Operator Werner Lanthaler I would now like to turn the conference over to Werner Lanthaler, CEO. Please go ahead. Thank you very much. Welcome to all of you. Welcome to o ...